We examined case reports of immune checkpoint inhibitors (ICIs) associated pulmonary tuberculosis (PT) using data from the Food and Drug Administration Adverse Event Reporting System database. Disproportionality analysis was performed by using the reporting OR (ROR) with relevant 95% CI. A total of 74 cases of PT related to ICIs therapy were identified. ICIs were significantly associated with over-reporting frequencies of PT (ROR=3.16, 95% CI: 2.51 to 3.98), while the signal was differed between anti-programmed death-1/ligand-1 and anti-cytotoxic T lymphocyte antigen-4 agents. Most indications were lung cancer (64.9%), the median onset age was 70 years, the median time to onset of PT was 70 days, ICIs were discontinued in most cases (85.2%).

中文翻译：

---

与免疫检查点抑制剂相关的肺结核：药物警戒研究

我们使用来自食品和药物管理局不良事件报告系统数据库的数据检查了免疫检查点抑制剂 (ICI) 相关肺结核 (PT) 的病例报告。通过使用具有相关 95% CI 的报告 OR (ROR) 进行不成比例分析。共确定了 74 例与 ICI 治疗相关的 PT。ICI 与 PT 的过度报告频率显着相关（ROR=3.16，95% CI：2.51 至 3.98），而抗程序性死亡 1/配体 1 和抗细胞毒性 T 淋巴细胞抗原 4 之间的信号不同代理。大多数适应症为肺癌（64.9%），中位发病年龄为 70 岁，中位 PT 发病时间为 70 天，大多数情况下停用 ICI（85.2%）。